NK and T cells infiltrating BRAFi‐sensitive tumors also expressed higher levels of NKG2D to recognize transformed cells, but tumor cells downregulated NKG2D ligands indicating another mechanism how BRAFi‐treated tumors might evade immune recognition. Here, KLRK1 is linked to neoplasm.